Is Dacomitinib/Dozerun a targeted drug or a chemotherapy drug?

In the treatment of lung cancer, one of the issues that patients are most concerned about is the type and mode of action of the drug. Dacomitinib/Dacomitinib (Dacomitinib) is clearly classified as a targeted drug, rather than a chemotherapy drug in the traditional sense. There are essential differences between the two in their mechanisms and modes of action. Chemotherapy drugs are characterized by killing tumor cells by blocking the division of cancer cells, but they also affect normal cells in the body, so side effects are common. As a targeted drug, dacomitinib intervenes in the growth and spread of tumors by selectively inhibiting specific molecular pathways. It is mainly targeted at patients with non-small cell lung cancer who have sensitive mutations in the epidermal growth factor receptor (EGFR) gene. Compared with chemotherapy, dacomitinib has a more precise effect. It can inhibit the activity of EGFR-related signaling pathways, thereby reducing the proliferation and metastasis risk of tumor cells.

In recent years, with the development of molecular biology, the clinical status of dacomitinib has gradually improved, and it is considered a representative drug among the second generationEGFR tyrosine kinase inhibitors. One of its outstanding features is that it irreversibly binds to the EGFR receptor family, covering EGFR, HER2 and HER4, thereby expanding the scope of inhibition. Compared with first-generation EGFR inhibitors, dacomitinib has a more durable effect in delaying disease progression. Globally, it is widely used in patients with newly treated EGFR mutant non-small cell lung cancer, providing many patients with a new treatment option in addition to chemotherapy.

In terms of usage experience, patients generally report that dacomitinib is more controllable in managing side effects. Although common reactions related to EGFR inhibition, such as rash, diarrhea, and oral inflammation, may occur, it is generally well tolerated and does not cause severe bone marrow suppression or widespread hair loss like traditional chemotherapy. This is one of the reasons why many patients prefer targeted drugs over chemotherapy. Combined with the recommendations of guidelines, dacomitinib has become the core drug for the first-line treatment of EGFR mutant lung cancer.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro